Pharma sector doubles down on AI to slash costs, timelines
SPY•SPY•SPY•SPY•Pharmaceutical companies are increasingly using AI in research and development, with industry forecasts suggesting machine learning could halve early-stage development timelines and costs within three to five years. The article lists partnerships and deals announced from 2025 through October 2026, including collaborations involving Merck KGaA and Boehringer Ingelheim.
Pharmaceutical companies are turning to AI modeling tools and automated laboratories to improve research and development efficiency. Industry forecasts suggest machine learning could halve early-stage development timelines and costs within the next three to five years.
The listed agreements span drug discovery, clinical research, manufacturing and healthcare operations. Recent examples include Merck KGaA partnering with Microsoft, Nvidia and Dawn Health to provide personalized support for patients with rare tumors, and Boehringer Ingelheim working with Microsoft on digital patient twins for human and animal health.
